Manidipino Teva-Ratiopharm

Manidipine, the active ingredient in Manidipino Teva‑Ratiopharm, is a calcium channel blocker presented as an oral tablet for oral use. It is used to treat hypertension in adult patients and helps lower elevated blood pressure by relaxing vascular smooth muscle.

GNH USA supplies Manidipino Teva‑Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine is a dihydropyridine calcium‑channel blocker indicated for the management of hypertension and related blood‑pressure disorders.

- Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: reduces elevated systolic pressure, especially in older adults. - Renovascular hypertension: assists in controlling blood pressure when renal artery narrowing contributes to hypertension.

Manidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Nausea or abdominal discomfort. - Tachycardia: slight increase in heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with Manidipine, clinicians should consider several safety aspects.

- Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: adjust use in patients with liver disease. - Concomitant antihypertensives: watch for additive hypotensive effects. - Elderly patients: start at lower doses and monitor tolerance. - Discontinuation: avoid abrupt cessation; taper if needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Manidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other potent antihypertensives (e.g., ACE inhibitors, ARBs): risk of additive hypotension. - Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely): - Calcium or aluminum antacids: may reduce absorption; separate dosing by at least 2 hours. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt blood‑pressure‑lowering effect. - Beta‑blockers: monitor for combined cardiac effects. - Diuretics: watch for electrolyte disturbances and enhanced hypotension.